December 15, 2016
Survey: How would you improve pharmaceuticaldaily?
As some of you might know, pharmaceuticaldaily.com has recently redesigned its website as it added some new features and has…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
December 15, 2016
COMP gives positive opinion on Hansa Medical’s orphan drug
Hansa Medical, a biopharmaceutical company focusing on novel immunomodulatory enzymes, has announced that the Committee for Orphan Medicinal Products (COMP)…
December 15, 2016
NOXXON/Merck to study drugs combination in cancer treatment
NOXXON Pharma N.V. has announced a collaboration with Merck & Co. (MSD), Inc, under which the two companies will collaborate…
December 15, 2016
Bioven gets green light for NSC cancer drug testing patient enrolment
A cancer-focused drug-maker Bioven can now enrol patients in the USA in its international Phase III trial of EGF-PTI, in…
December 15, 2016
Kiadis Pharma starts a P I/II clinical trial for thalassemia treatment
Kiadis Pharma N.V., a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders…
December 15, 2016
TiGenix raises $35.65M proceeds with NASDAQ IPO
A biopharmaceutical company TiGenix focused on allogeneic expanded stem cells, has raised $35.65 million gross proceeds from the sale of 2,300,000 American Depository…
December 15, 2016
Argenx launches P I/II clinical trial for acute myeloid leukemia treatment
Argenx, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe…
December 15, 2016
Pfizer/Astellas’s cancer drug study fails
Pfizer and Astellas Pharma have announced the Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with…
December 15, 2016
Biocartis CE-marks Idylla NRAS-BRAF Mutation Test
Biocartis has CE-marked its solid biopsy Idylla NRAS-BRAF Mutation Test. On Thursday, Biocartis said that, together with the CE-marked Idylla…
December 15, 2016
PureTech health finishes tolerability testing of KarXT for schizophrenia and Alzheimer’s
Karuna Pharmaceuticals and a subsidiary of PureTech Health have finished studying antipsychotic for schizophrenia and Alzheimer’s disease – KarXT. The…